ARIPIPRAZOLE tablet United States - English - NLM (National Library of Medicine)

aripiprazole tablet

alembic pharmaceuticals inc. - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 2 mg - aripiprazole is indicated for the treatment of: •  schizophrenia •  irritability associated with autistic disorder •  treatment of tourette’s disorder additional pediatric use information is approved for otsuka america pharmaceutical, inc.’s abilify® (aripiprazole) product. however, due to otsuka america pharmaceutical, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. aripiprazole is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. reactions have ranged from pruritus/urticaria to anaphylaxis [see adverse reactions  (6.2)]. pregnancy exposure registry   there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy. healthcare providers are encouraged to register patients by contacting the national pregnancy registry for atypical antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-progr

LAXATIVE PILLS MAXIMUM STRENGTH- sennosides tablet United States - English - NLM (National Library of Medicine)

laxative pills maximum strength- sennosides tablet

good sense (geiss, destin & dunn, inc.) - sennosides (unii: 3fyp5m0ijx) (sennosides - unii:3fyp5m0ijx) - stimulant laxative - relieves occasional constipation (irregularity) - generally produces bowel movement in 6 to 12 hours

Buscopan Plus Tablets Kenya - English - Pharmacy and Poisons Board

buscopan plus tablets

boehringer ingelheim 407 pine avenue, ferndale, randburg, rsa - hyoscine butylbromide and paracetamol - tablet - 10 mg hyoscine butylbromide/ tablet & 500 mg… - other antispasmodics in combination with

SPASMORID-M Tablet Kenya - English - Pharmacy and Poisons Board

spasmorid-m tablet

galaxy pharmaceutical limited 1st floor, doctor's park 3rd parklands avenue - drotaverine hydrochloride & mefenamic acid - tablet - drotaverine hcl 80 mg and mefenamic acid 250 mg… - other antispasmodics in combination with

Adco Acyclovir Cream Kenya - English - Pharmacy and Poisons Board

adco acyclovir cream

adcock ingram ltd. p.o. box 101674-00101 nairobi - adco acyclovir cream - cream - each 1g contains acyclovir 0.05gms - antivirals for topical use

ADCO-ROZNAL CAPSULES South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adco-roznal capsules

adcock ingram limited - capsules - see ingredients - each capsule contains lansoprazole 30,0 mg

ADCO-OMEPRAZOLE 40 CAPSULES South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

adco-omeprazole 40 capsules

adcock ingram limited - capsules - see ingredients - each capsule contains omeprazole 40,0 mg

PADCEV enfortumab vedotin 30 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

padcev enfortumab vedotin 30 mg powder for injection vial

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 30 mg - injection, powder for - excipient ingredients: polysorbate 20; histidine hydrochloride monohydrate; histidine; trehalose dihydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.

PADCEV enfortumab vedotin 20 mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

padcev enfortumab vedotin 20 mg powder for injection vial

astellas pharma australia pty ltd - enfortumab vedotin, quantity: 20 mg - injection, powder for - excipient ingredients: polysorbate 20; trehalose dihydrate; histidine; histidine hydrochloride monohydrate - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand-1 inhibitor.